EE04912B1 - N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina - Google Patents

N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina

Info

Publication number
EE04912B1
EE04912B1 EEP200100233A EEP200100233A EE04912B1 EE 04912 B1 EE04912 B1 EE 04912B1 EE P200100233 A EEP200100233 A EE P200100233A EE P200100233 A EEP200100233 A EE P200100233A EE 04912 B1 EE04912 B1 EE 04912B1
Authority
EE
Estonia
Prior art keywords
arylpropion
sulfonamides
inhibitors
pharmaceutical compositions
compositions containing
Prior art date
Application number
EEP200100233A
Other languages
English (en)
Estonian (et)
Inventor
Bertini Riccardo
Bizzarri Cinzia
Sabbatini Vilma
Porzio Stefano
Caselli Gianfranco
Allegretti Marcello
Candida Cesta Maria
A. Gandolfi Carmelo
Mantovanini Marco
Colotta Francesco
Original Assignee
Domp S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domp S.P.A. filed Critical Domp S.P.A.
Publication of EE200100233A publication Critical patent/EE200100233A/xx
Publication of EE04912B1 publication Critical patent/EE04912B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
EEP200100233A 1998-10-23 1999-10-14 N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina EE04912B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002280A IT1303249B1 (it) 1998-10-23 1998-10-23 Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
PCT/EP1999/007740 WO2000024710A1 (en) 1998-10-23 1999-10-14 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them

Publications (2)

Publication Number Publication Date
EE200100233A EE200100233A (et) 2002-08-15
EE04912B1 true EE04912B1 (et) 2007-10-15

Family

ID=11380926

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100233A EE04912B1 (et) 1998-10-23 1999-10-14 N-(2-arlpropionl)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina

Country Status (26)

Country Link
US (2) US6887903B1 (de)
EP (1) EP1123276B1 (de)
JP (1) JP4194761B2 (de)
KR (1) KR100484370B1 (de)
CN (2) CN1615833A (de)
AT (1) ATE230723T1 (de)
AU (1) AU769850B2 (de)
BR (1) BRPI9914741B8 (de)
CA (1) CA2347752C (de)
CZ (1) CZ296434B6 (de)
DE (1) DE69904852T2 (de)
DK (1) DK1123276T3 (de)
EE (1) EE04912B1 (de)
ES (1) ES2190264T3 (de)
HK (1) HK1041255B (de)
HU (1) HU225107B1 (de)
IL (1) IL142496A0 (de)
IT (1) IT1303249B1 (de)
NO (1) NO327537B1 (de)
NZ (2) NZ511077A (de)
PL (1) PL212210B1 (de)
PT (1) PT1123276E (de)
RU (1) RU2255084C2 (de)
SK (1) SK286372B6 (de)
TR (1) TR200101124T2 (de)
WO (1) WO2000024710A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318466B1 (it) * 2000-04-14 2003-08-25 Dompe Spa Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria.
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
US20060247297A1 (en) * 2002-12-10 2006-11-02 Marcello Allegretti Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases
EP1457485A1 (de) * 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonsäuren, deren Derivate sowie sie enthaltenden pharmazeutischen Zubereitungen
WO2004111012A1 (ja) * 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
PT1776336E (pt) * 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
PT1579859E (pt) * 2004-03-25 2007-03-30 Dompe Pha R Ma Spa Res & Mfg Utilização de n-(2-aril-propionil)-sulfonamidas pata o tratamento de lesões da medula espinal
NZ555502A (en) * 2004-12-15 2010-12-24 Dompe Pha R Ma Spa Res & Mfg 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
US20090131441A1 (en) * 2005-01-25 2009-05-21 Dompe Phar.R.Ma S.P.A. Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them
RS55192B1 (sr) * 2005-11-24 2017-01-31 Dompé Farm S P A Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže
WO2010009212A1 (en) * 2008-07-17 2010-01-21 Schering Corporation Niacin derivatives useful to treat metabolic syndromes
EP2166006A1 (de) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-Arylpropionsäuren und -Derivate und pharmazeutische Zusammensetzungen, die diese enthalten
EP2308485A1 (de) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamide zur Diabetesprävention
EP2308484A1 (de) 2009-10-06 2011-04-13 Dompé S.p.a. Hemmer von CXCRL1/2 als Adjuvanzien bei der Transplantation von Langerhans-Zellen
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
CN103172547B (zh) * 2011-12-20 2016-10-12 天津市国际生物医药联合研究院 磺酰胺衍生物的制备及其应用
CN103159674A (zh) * 2013-04-03 2013-06-19 苏州安诺生物医药技术有限公司 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途
US12268671B2 (en) 2016-01-15 2025-04-08 Dompé Farmaceutici S.P.A. IL-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
JP7252125B2 (ja) 2016-10-03 2023-04-04 ザ チルドレンズ メディカル センター コーポレーション 糖尿病性腎症の予防および処置
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
EP3409277A1 (de) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8-inhibitoren zur verwendung bei der behandlung und/oder prävention von bakteriellen sekundärinfektionen
EP3476390A1 (de) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8-inhibitoren zur verwendung bei der behandlung von sarkomen
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
EP3868368A1 (de) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Inhibitor der aktivität von cxcl8 (interleukin-8) und corticosteroidkombination und pharmazeutische zusammensetzung und verwendung davon
EP3868369A1 (de) 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitor und pharmazeutische zusammensetzung davon zur verwendung in der behandlung von krebsbedingter ermüdung
US20230141355A1 (en) 2020-03-26 2023-05-11 Dompe' Farmaceutici Spa Cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (de) 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19
EP3884932A1 (de) 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von covid-19
IL302553A (en) * 2020-11-05 2023-07-01 Icahn School Med Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (de) 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8-inhibitor und dessen pharmazeutische zusammensetzung zur verwendung bei der behandlung von krampfanfällen
EP4397305A1 (de) 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8-inhibitoren zur verwendung bei der behandlung von augenschleimhaut-pemphigoid und/oder mundschleimhaut-pemphigoid
EP4563594A1 (de) 2023-11-28 2025-06-04 Dompe' Farmaceutici SpA Cxcl8-inhibitoren zur verwendung bei der behandlung von tumoren mit niedrigem stroma-cav1-gehalt
EP4678171A1 (de) 2024-07-10 2026-01-14 Dompé farmaceutici SpA Systemisch verabreichte cxcl8-inhibitoren zur verwendung bei der vorbeugung oder behandlung von augenschleimhaut-pemphigoid und/oder mundschleimhaut-pemphigoid
EP4686469A1 (de) 2024-07-31 2026-02-04 Dompé farmaceutici SpA Cxcl8-inhibitoren zur verwendung bei der behandlung von diabetes-assoziierten erkrankungen
EP4686472A1 (de) 2024-08-02 2026-02-04 Dompé farmaceutici SpA Cxcl8-inhibitoren zur verwendung bei der behandlung von graft-versus-host-reaktion des auges

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082707A (en) 1973-01-08 1978-04-04 Societa Italo-Britannica L. Manetti-H. Roberts & Co. 2-(4-isobutylphenyl)-propiohydroxamic acid and a procedure for its preparation
JPS53111030A (en) * 1977-02-08 1978-09-28 Hisamitsu Pharmaceut Co Inc Novel phenylacetic acid derivatives
US4786316A (en) * 1984-07-13 1988-11-22 E. I. Du Pont De Nemours And Company Herbicidal ortho-sulfamoyl sulfonamides
US5006542A (en) * 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
JPH06506596A (ja) * 1991-04-10 1994-07-28 ザ　トラスティーズ　オブ　ボストン　ユニバーシティー インターロイキン−８受容体及び関連分子及び方法
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
CA2502764A1 (en) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
US6214881B1 (en) * 1996-08-21 2001-04-10 Smithkline Beecham Corporation IL-8 receptor antagonists
JP3573757B2 (ja) * 1997-01-29 2004-10-06 ファイザー・インク スルホニルウレア誘導体、およびインターロイキン−１の活性を制御する上でのスルホニルウレア誘導体の使用

Also Published As

Publication number Publication date
CZ296434B6 (cs) 2006-03-15
KR100484370B1 (ko) 2005-04-22
HU225107B1 (en) 2006-06-28
JP2002528434A (ja) 2002-09-03
ITMI982280A0 (it) 1998-10-23
US6887903B1 (en) 2005-05-03
DE69904852T2 (de) 2003-11-13
HK1041255B (zh) 2008-07-18
NO327537B1 (no) 2009-08-03
EP1123276A1 (de) 2001-08-16
BRPI9914741B1 (pt) 2012-11-27
DK1123276T3 (da) 2003-04-28
NZ525084A (en) 2004-08-27
ATE230723T1 (de) 2003-01-15
HUP0103793A3 (en) 2003-09-29
PL347947A1 (en) 2002-04-22
PT1123276E (pt) 2003-04-30
NO20012000L (no) 2001-06-20
HUP0103793A2 (hu) 2002-03-28
ES2190264T3 (es) 2003-07-16
AU1037500A (en) 2000-05-15
US20030216392A1 (en) 2003-11-20
CN1615833A (zh) 2005-05-18
RU2255084C2 (ru) 2005-06-27
CA2347752C (en) 2009-12-22
PL212210B1 (pl) 2012-08-31
BRPI9914741A (pt) 2001-07-03
AU769850B2 (en) 2004-02-05
EE200100233A (et) 2002-08-15
IL142496A0 (en) 2002-03-10
KR20010086435A (ko) 2001-09-12
CN100368394C (zh) 2008-02-13
WO2000024710A1 (en) 2000-05-04
CN1324344A (zh) 2001-11-28
CZ20011441A3 (cs) 2001-10-17
SK286372B6 (sk) 2008-08-05
CA2347752A1 (en) 2000-05-04
US6881755B2 (en) 2005-04-19
HK1041255A1 (zh) 2002-07-05
IT1303249B1 (it) 2000-11-06
NO20012000D0 (no) 2001-04-23
NZ511077A (en) 2003-08-29
JP4194761B2 (ja) 2008-12-10
ITMI982280A1 (it) 2000-04-23
EP1123276B1 (de) 2003-01-08
SK5382001A3 (en) 2001-12-03
TR200101124T2 (tr) 2001-10-22
BRPI9914741B8 (pt) 2021-07-06
DE69904852D1 (de) 2003-02-13

Similar Documents

Publication Publication Date Title
EE200100233A (et) N-(2-arüülpropionüül)sulfoonamiidid, neid sisaldavad farmatseutilised kompositsioonid ning kasutamine inhibiitorina
CA2318145A1 (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
DK1259485T3 (da) Benzamider og beslægtede inhibitorer for faktor Xa
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
ECSP045378A (es) Derivados novedosos de diazabiciclononeno
DE69933897D1 (de) Carbamat und Carbazat Ketolid Antibiotika
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
PT992509E (pt) Novos derivados macrolidos
IL136359A (en) Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same
ATE318810T1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
IL140070A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
DE59903759D1 (de) Ektoparasitizide mittel
BR0212899A (pt) Compostos orgânicos
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
DE60005517D1 (de) Kaliumkanal-blockierende mittel
ATE207063T1 (de) Uracilderivate
FR2707496B1 (fr) Compositions pharmaceutiques antiradicalaires et/ou antilipoperoxydantes et/ou hépatotropes.
ATE469884T1 (de) Indolinverbindung und deren medizinische verwendung
SE9902596D0 (sv) Pharmaceutically active compounds

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

GB1A Change in the ownership or in the address of the owner